Business Wire

www.businesswire.com
1 min read
fairly difficult
Rubraca® (Rucaparib) Approved in the U.S. as Monotherapy Treatment for Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer (mCRPC) Who Have Been Treated with Androgen Receptor-Directed Therapy and a Taxane-Based Chemotherapy  Business WireBREAKING NEWS: FDA Approves Rucaparib For Treatment of Advanced Prostate Cancer  Prostate Cancer FoundationView Full Coverage on Google News
Business Wire's Website is Currently Unavailable

We apologize for the…
Read full article